T

TG Therapeutics
D

TGTX

43.390
USD
-1.96
(-4.32%)
مغلق
حجم التداول
220,146
الربح لكل سهم
1
العائد الربحي
-
P/E
293
حجم السوق
6,815,292,249
أصول ذات صلة
INCY
INCY
0.500
(0.81%)
62.500 USD
K
KPTI
0.70000
(10.37%)
7.45000 USD
N
NKTR
-0.02630
(-3.38%)
0.75210 USD
المزيد
الأخبار المقالات

العنوان: TG Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T),and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.